ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P 500
5,277.51
0.80%
US Tech 100
18,064.80
0.02%
Dow Jones
38,686.32
1.51%
Brent Oil
81.295
0.00%
Bitcoin
67,745.54
0.39%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. Europe
  5. EU
  6. Ab Science (AB)

  7. Ab Science (AB) News

AB

Ab Science (AB)

Ab Science
Date:
Sort by:
 Showing the most relevant articles for your search:EU:AB
DateTimeSourceHeadlineSymbolCompany
05/31/202410:30AMGlobeNewswire Inc.AB Science is providing a summary of the live webcast held on May 30, 2024, giving an update on the application for conditional marketing authorization of masitinib in ALSEU:ABAb Science
05/31/202410:30AMGlobeNewswire Inc.AB Science is providing a summary of the live webcast held on May 30, 2024, giving an update on the application for conditional marketing authorization of masitinib in ALSEU:ABAb Science
05/31/202410:30AMGlobeNewswire Inc.AB Science fournit un résumé de la conférence virtuelle qui s'est tenue le 30 mai 2024, faisant le point sur la demande d'autorisation de mise sur le marché conditionnelle du masitinib dans la SLAEU:ABAb Science
05/29/202412:02PMGlobeNewswire Inc.AB Science fait le point sur la demande d'autorisation de mise sur le marché conditionnelle du masitinib dans la SLAEU:ABAb Science
05/29/202412:02PMGlobeNewswire Inc.AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALSEU:ABAb Science
05/29/202412:02PMGlobeNewswire Inc.AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALSEU:ABAb Science
05/17/202411:58AMGlobeNewswire Inc.AB Science communique un rectificatif sur les comptes consolidés au 31 décembre 2023EU:ABAb Science
05/15/20242:16PMGlobeNewswire Inc.AB Science reports its revenues for the year 2023 and provides an update on its activitiesEU:ABAb Science
05/15/20242:16PMGlobeNewswire Inc.AB Science annonce ses résultats financiers annuels arrêtés au 31 décembre 2023 et présente un point sur ses activitésEU:ABAb Science
05/15/20242:16PMGlobeNewswire Inc.AB Science reports its revenues for the year 2023 and provides an update on its activitiesEU:ABAb Science
05/13/202412:08PMGlobeNewswire Inc.AB Science announces issuance of a European patent for masitinib in the treatment of severe mastocytosis with protection until 2036EU:ABAb Science
05/13/202412:08PMGlobeNewswire Inc.AB Science annonce la délivrance d’un brevet européen pour le masitinib dans le traitement de la mastocytose sévère avec une protection jusqu’en 2036EU:ABAb Science
05/13/202412:08PMGlobeNewswire Inc.AB Science announces issuance of a European patent for masitinib in the treatment of severe mastocytosis with protection until 2036EU:ABAb Science
05/07/202412:05PMGlobeNewswire Inc.AB Science : A new publication in the medical journal Muscle & Nerve validates the use of the rate of decline of ALSFR-S score (ΔFS) for the design of clinical studies and the treatment choice for amyotrophic lateral sclerosis (ALS) patientEU:ABAb Science
05/07/202412:05PMGlobeNewswire Inc.AB Science : A new publication in the medical journal Muscle & Nerve validates the use of the rate of decline of ALSFR-S score (ΔFS) for the design of clinical studies and the treatment choice for amyotrophic lateral sclerosis (ALS) patientEU:ABAb Science
05/07/202412:05PMGlobeNewswire Inc.AB Science:EU:ABAb Science
05/02/20241:14PMGlobeNewswire Inc.AB Science : The Paris Court of Appeal confirms the acquittal of the CEO of AB Science, Alain Moussy, and reduces the amount of the financial penalty imposed on AB ScienceEU:ABAb Science
05/02/20241:14PMGlobeNewswire Inc.AB Science : The Paris Court of Appeal confirms the acquittal of the CEO of AB Science, Alain Moussy, and reduces the amount of the financial penalty imposed on AB ScienceEU:ABAb Science
05/02/20241:14PMGlobeNewswire Inc.AB Science : La Cour d’Appel de Paris confirme la mise hors de cause du Président Directeur Général d’AB Science, Alain Moussy, et diminue le montant de la sanction imposée à AB ScienceEU:ABAb Science
04/30/202412:56PMGlobeNewswire Inc.AB Science announces a slight delay in the publication of its 2023 annual financial reportEU:ABAb Science
04/30/202412:56PMGlobeNewswire Inc.AB Science announces a slight delay in the publication of its 2023 annual financial reportEU:ABAb Science
04/30/202412:56PMGlobeNewswire Inc.AB Science annonce un léger décalage de la publication de son rapport financier annuel 2023EU:ABAb Science
04/03/202412:08PMGlobeNewswire Inc.AB Science annonce que Santé Canada a jugé admissible la demande de réexamen du masitinib dans SLAEU:ABAb Science
04/03/202412:08PMGlobeNewswire Inc.AB Science announces that Health Canada has granted eligibility for reconsideration request for masitinib in ALSEU:ABAb Science
03/13/20247:58AMGlobeNewswire Inc.AB Science: New research shows that masitinib limits neuronal damage in a model of neuroimmune-driven neurodegenerative diseaseEU:ABAb Science
03/13/20247:58AMGlobeNewswire Inc.AB Science : De nouvelles recherches montrent que le masitinib limite les dommages neuronaux dans un modèle de maladie neurodégénérative d’origine neuroimmuneEU:ABAb Science
03/13/20247:58AMGlobeNewswire Inc.AB Science: New research shows that masitinib limits neuronal damage in a model of neuroimmune-driven neurodegenerative diseaseEU:ABAb Science
03/07/20249:20AMGlobeNewswire Inc.AB Science provides a summary of the live webcast held on March 4, 2024 giving an update on AB Science developmentEU:ABAb Science
03/07/20249:20AMGlobeNewswire Inc.AB Science propose un résumé de la conférence virtuelle qui s’est tenue le 4 mars 2024, avec pour objectif de faire le point sur le développement d'AB ScienceEU:ABAb Science
03/07/20249:20AMGlobeNewswire Inc.AB Science provides a summary of the live webcast held on March 4, 2024 giving an update on AB Science developmentEU:ABAb Science
 Showing the most relevant articles for your search:EU:AB

Your Recent History

USOTC
HMBL
HUMBL (PK)
AMEX
FOXO
FOXO Technologies
USOTC
CATV
4Cable TV (PK)
USOTC
DRNK
NoHo (PK)
USOTC
TPTW
TPT Global Tech (PK)
USOTC
GNCP
GNCC Capital (CE)
USOTC
RSPI
RespireRx Pharmaceuticals (PK)
USOTC
CYDY
CytoDyn (QB)
NASDAQ
COOP
Mr Cooper
USOTC
IFUS
Impact Fusion (PK)
USOTC
FSRN
Fisker (PK)
USOTC
KEGS
1812 Brewing (PK)
USOTC
VPLM
Voip Pal Com (QB)
USOTC
MWWC
Marketing Worldwide (PK)
USOTC
RNVA
Rennova Health (PK)
USOTC
CEOS
CeCors (PK)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved